@article{0c72784f67b349e9918582be236423b7,
title = "Systematic review of atopic dermatitis disease definition in studies using routinely collected health data",
abstract = "Background: Routinely collected electronic health data obtained for administrative and clinical purposes are increasingly used to study atopic dermatitis (AD). Methods for identifying AD patients in routinely collected electronic health data differ, and it is unknown how this might affect study results. Objectives: To evaluate how patients with AD have been identified in studies using routinely collected electronic health data, to determine whether these methods were validated and to estimate how the method for identifying patients with AD affected variability in prevalence estimates. Methods: We systematically searched PubMed, Embase and Web of Science for studies using routinely collected electronic health data that reported on AD as a primary outcome. Studies of localized AD and other types of dermatitis were excluded. The protocol for this review was registered in PROSPERO (CRD42016037968). Results: In total, 59 studies met eligibility criteria. Medical diagnosis codes for inclusion and exclusion, number of occasions of a code, type of provider associated with a code and prescription data were used to identify patients with AD. Only two studies described validation of their methods and no study reported on disease severity. Prevalence estimates ranged from 0·18% to 38·33% (median 4·91%) and up to threefold variation in prevalence was introduced by differences in the method for identifying patients with AD. Conclusions: This systematic review highlights the need for clear reporting of methods for identifying patients with AD in routinely collected electronic health data to allow for meaningful interpretation and comparison of results.",
author = "Dizon, {M. P.} and Yu, {A. M.} and Singh, {R. K.} and J. Wan and Chren, {M. M.} and C. Flohr and Silverberg, {J. I.} and Margolis, {D. J.} and Langan, {S. M.} and K. Abuabara",
note = "Funding Information: This study was supported in part by the University of California, San Francisco Resource Allocation Program for Trainees (RAPtr). K.A. is supported by grants from the Dermatology Foundation and National Center for Advancing Translational Sciences of the National Institutes of Health (NIH) under Award Number KL2TR001870. Research reported in this publication is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. C.F. is funded through a UK National Institute for Health Research (NIHR) Career Development Fellowship (CDF-2014-07-037). The views expressed are those of the author(s) and not necessarily those of the UK National Health Service, the UK NIHR, or the UK Department of Health. S.M.L. is supported by a Wellcome senior clinical fellowship in science (205039/Z/16/Z). J.I.S. is supported by grants from the AHRQ K12 HS023011 and Dermatology Foundation. The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript. Funding Information: J.W. receives research funding from the National Institutes of Health (NIH), the Dermatology Foundation and the American Skin Association. D.J. M. receives research funding from the NIH, Leo Pharma and Valeant, and he is a consultant for Sanofi and GlaxoSmithKline. K.A. receives research funding from the NIH, the Dermatology Foundation and the Robert Wood Johnson Foundation. Publisher Copyright: {\textcopyright} 2018 The Authors. British Journal of Dermatology published by John Wiley & Sons Ltd on behalf of British Association of Dermatologists.",
year = "2018",
month = jun,
doi = "10.1111/bjd.16340",
language = "English (US)",
volume = "178",
pages = "1280--1287",
journal = "British Journal of Dermatology",
issn = "0007-0963",
publisher = "Wiley-Blackwell",
number = "6",
}